L74.F WuXi XDC Cayman Inc.
- Market cap
- EUR 10.3B
- P/E
- 58.2x
- P/B
- 6.92x
- ROE
- 13.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is L74.F undervalued?
Graham numberThe Graham number of WuXi XDC Cayman Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WuXi XDC Cayman Inc. fundamental analysis
No fundamental analysis for WuXi XDC Cayman Inc. yet.
WuXi XDC Cayman Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WuXi XDC Cayman Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting service…
Full company profileWuXi XDC Cayman Inc. financial statements
WuXi XDC Cayman Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 311M | 990M | 2.12B | 4.05B | 5.94B |
| Gross Profit | 113M | 261M | 560M | 1.24B | 2.14B |
| Operating Income | 60.1M | 142M | 402M | 949M | 1.67B |
| EBITDA | - | 230M | 420M | 1.33B | 1.90B |
| Net Income | 54.9M | 156M | 284M | 1.07B | 1.48B |
| EPS | 0.05 | 0.13 | 0.24 | 0.89 | 1.18 |
| Balance Sheet | |||||
| Total Assets | 880M | 2.50B | 6.74B | 9.12B | 14.4B |
| Total Liabilities | 859M | 1.02B | 1.28B | 2.48B | 3.71B |
| Shareholders' Equity | 20.9M | 1.48B | 5.45B | 6.64B | 10.7B |
| Cash & Short-term Investments | 26.3M | 335M | 4.05B | 1.93B | 1.51B |
| Cash Flow | |||||
| Operating Cash Flow | 59.1M | 252M | 333M | 717M | 1.78B |
| Capital Expenditure | 51.9M | 201M | 539M | 1.51B | 1.26B |
| Free Cash Flow | 7.23M | 50.4M | -207M | -788M | 524M |
| Ratios | |||||
| ROE | 263.1% | 10.5% | 5.2% | 16.1% | 13.8% |
| ROA | 6.2% | 6.2% | 4.2% | 11.7% | 10.3% |
| Net Profit Margin | 17.7% | 15.7% | 13.4% | 26.4% | 24.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
WuXi XDC Cayman Inc. dividends
WuXi XDC Cayman Inc. has not paid dividends in the last 5 fiscal years.
Who owns WuXi XDC Cayman Inc.
- Insiders 64.54%
- Institutions 20.18%
- Public & others 15.27%
- Shares outstanding 1.27B
- Free float 443M
WuXi XDC Cayman Inc. company profile
- Company name
- WuXi XDC Cayman Inc.
- Ticker
- L74.F
- ISIN
- KYG9808A1058
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 3,628
- Fiscal year end
- December
- Address
- No. 11 Xinhui Ring Road, Wuxi, China
- Website
- wuxixdc.com
About WuXi XDC Cayman Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
WuXi XDC Cayman Inc. management
7- Dr. Jincai Li Ph.D.CEO & Executive Director · born 1973
- Mr. Xiaojie XiCFO & Executive Director · born 1976
- Mr. Jingwei ZhangCOO & Executive Director · born 1969
- Dr. Meiying ZhuChief Technology Officer · born 1966
- Ms. Yuan FangJoint Company Secretary, Head of IR, Capital Markets, Corporate Communication and Public Affairs
- Ms. Man Nar ChungJoint Company Secretary
- Dr. Jianjun LuoVice President · born 1968